🇺🇸 FDA
Patent

US 8940301

Breast tumor treatment with anti-CXCR1 compositions

granted A61KA61K31/18A61K31/337

Quick answer

US patent 8940301 (Breast tumor treatment with anti-CXCR1 compositions) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/18, A61K31/337, A61K45/06, A61P